<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Effects of a novel calcium 2+ <z:chebi fb="68" ids="48706">antagonist</z:chebi>, KB-2796, on neurologic outcome and size of infarction were studied in the rat model of focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Neurologic deficits were examined from 1 to 24 hours after occlusion of the middle cerebral artery and size of infarction was measured at 24 hours postocclusion </plain></SENT>
<SENT sid="2" pm="."><plain>When KB-2796 (10 mg/kg, IP) was given immediately after, or 1 hour after, middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, marked improvement in neurologic score was seen 1 to 3 hours postocclusion </plain></SENT>
<SENT sid="3" pm="."><plain>When given immediately after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, size of infarction was also markedly smaller when compared with the control rat </plain></SENT>
<SENT sid="4" pm="."><plain>The present study suggests that the calcium 2+ <z:chebi fb="68" ids="48706">antagonist</z:chebi> KB-2796 has brain-protective effects against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> even with its administration after induction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
</text></document>